UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 13, 2016
Emmaus Life Sciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | | 000-53072 | | 41-2254389 |
(State or Other Jurisdiction of
Incorporation | | (Commission File Number) | | (IRS Employer
Identification No.) |
21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503
(Address, including zip code, off principal executive offices)
Registrant’s telephone number, including area code 310-214-0065
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On December 13, 2016, Emmaus Life Sciences, Inc., issued a press release announcing the allowance of patent application number 2014-547181, directed to the treatment of diverticulosis, by the Japanese Patent Office. The allowance of this application follows the issuance of corresponding patents in both Australia (Pat. No. 2012355956, November 3, 2016) and China (Pat. No. 104114165, October 19, 2016). Related patent applications are currently pending in various jurisdictions around the world, including the United States, Europe, South Korea, Brazil, Russia, India, Mexico and Indonesia. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit No. | | Description |
99.1 | | Emmaus press release dated December 13, 2016 re: Emmaus Life Sciences, Inc. Receives Japanese Patent for use of L-glutamine in Treatment of Diverticulosis. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 15, 2016 | Emmaus Life Sciences, Inc. |
| |
| |
| By: | /s/ YUTAKA NIIHARA |
| Name: | Yutaka Niihara |
| Title: | Chief Executive Officer |
3
Exhibit Index
Exhibit No. | | Description |
99.1 | | Emmaus press release dated December 13, 2016 re: Emmaus Life Sciences, Inc. Receives Japanese Patent for use of L-glutamine in Treatment of Diverticulosis. |
4
